The Biotechnology Research Group based out of Pune was established 3 years ago. The vision of this group is to develop and commercialize Bio-Similars and New Biological Entities for the Company. Lupinís state-of-the-art Biotech research & manufacturing facility has already been approved by the Institutional Bio Safety Committee (IBSC) for research on recombinant DNA. Furthermore, this facility has also been accredited as a Biotech Centre by the Bioinformatic Centre of the University of Pune. Biotechnology research within the R&D value chain would be one of the key pillars of Lupinís future business strategy and success as a global pharmaceutical powerhouse.
Lupin currently has close to 100 scientists working at this dedicated facility. Research in different therapeutic areas encompassing oncology and immunology is being conducted here. Consequently, the biotechnology division has eight different protein therapeutics in different stages of development with two of the most advanced products about to commence clinical trials.
The Company has also commissioned state-of-the- art cGMP manufacturing facilities for microbial as well as mammalian derived proteins. The division has filed 13 patents for proprietary technologies that have been developed in-house and published 19 research articles.
Lupin is now looking to launch its first Biological in the Indian market by next fiscal. It is also exploring collaborative opportunities in the field of new biological formulations and new biological entities.